Optimal Monitoring Schedule for NovoMix 30 (Insulin Aspart Protamine/Aspart) Pre-Meal Therapy
For patients on NovoMix 30 given before meals, perform self-monitoring of blood glucose (SMBG) at a minimum of 4 times daily: fasting (pre-breakfast), pre-dinner, and 1–2 hours after breakfast and dinner to capture both basal and postprandial control. 1, 2, 3
Core Monitoring Framework
Minimum Essential Testing Points
Fasting glucose (pre-breakfast): Target 80–130 mg/dL to assess overnight basal coverage and guide morning NovoMix 30 dose 3, 4
Pre-dinner glucose: Target 80–130 mg/dL to evaluate daytime basal control and guide evening NovoMix 30 dose 3, 4
1–2 hour post-breakfast glucose: Target <180 mg/dL to assess adequacy of the rapid-acting component (30% insulin aspart) from the morning dose 2, 3, 1
1–2 hour post-dinner glucose: Target <180 mg/dL to evaluate prandial coverage from the evening dose 2, 3, 1
Rationale for This 4-Point Schedule
NovoMix 30 is a fixed-ratio biphasic insulin (70% protaminated insulin aspart for basal coverage + 30% rapid-acting insulin aspart for prandial coverage), administered twice daily before breakfast and dinner 1
Because the proportions of basal and prandial insulin are fixed and cannot be independently adjusted, monitoring must capture both components to guide total dose titration 1
The American Diabetes Association emphasizes that all insulin-treated patients require SMBG to monitor for hypoglycemia and guide therapy adjustments 4
Postprandial glucose measured 1–2 hours after meal initiation captures peak glucose levels and is the standard timing recommended by the ADA for assessing prandial insulin adequacy 2, 3
Enhanced Monitoring During Titration or Suboptimal Control
When to Intensify Testing Frequency
During initial dose titration: Increase to 6–7 times daily (add pre-lunch, bedtime, and occasional 3 AM checks) to detect hypoglycemia and refine dosing 4, 5
When HbA1c remains ≥7% despite target fasting glucose: Add structured postprandial testing after lunch to identify missed prandial excursions 2, 6
When fasting glucose is controlled (80–130 mg/dL) but HbA1c stays elevated: Postprandial hyperglycemia is the dominant contributor; prioritize 1–2 hour post-meal checks after all three meals 2, 6
Additional Testing Scenarios
Before and after exercise: To prevent exercise-induced hypoglycemia, especially if activity occurs within 2–4 hours of NovoMix 30 injection 4
During illness or stress: Increase frequency to every 4–6 hours, as insulin requirements may rise unpredictably 1
Suspected nocturnal hypoglycemia: Check at 2–3 AM if morning fasting glucose is unexpectedly high (Somogyi effect) or if nocturnal symptoms occur 4, 7
Interpreting Results and Adjusting Therapy
Dose Titration Principles
Titrate the morning NovoMix 30 dose based on pre-dinner and post-breakfast glucose values 1
Titrate the evening NovoMix 30 dose based on fasting (next morning) and post-dinner glucose values 1
In clinical trials, NovoMix 30 was titrated to achieve pre-meal glucose 80–110 mg/dL, with adjustments of ±2 to ±6 units per injection 1
Increase monitoring frequency during any dose change to detect hypoglycemia early 1, 4
When Fixed-Ratio Insulin Becomes Inadequate
If fasting glucose is at target but postprandial glucose consistently exceeds 180 mg/dL, the fixed 30% prandial component may be insufficient; consider switching to a basal-bolus regimen with separate rapid-acting insulin at meals 2, 1
If postprandial glucose is controlled but fasting glucose remains elevated, the 70% basal component may be inadequate; consider adding basal insulin or switching regimens 2
Critical Pitfalls to Avoid
Do not rely solely on fasting glucose when HbA1c remains elevated despite controlled fasting values—this misses the dominant postprandial contribution 2, 6
Do not test only pre-meal glucose in patients on biphasic insulin; postprandial testing is essential to assess the rapid-acting component 2, 3
Do not administer NovoMix 30 after meals (except in type 2 diabetes where it may be given immediately after meal initiation); the label specifies within 15 minutes before meals for optimal prandial coverage 1
Do not skip bedtime glucose checks during dose titration, as nocturnal hypoglycemia risk increases with evening NovoMix 30 4, 7
Avoid injecting into areas of lipohypertrophy, as this causes erratic absorption and unpredictable glucose control; rotate injection sites within abdomen, thighs, buttocks, or upper arms 1, 5
Role of HbA1c in Long-Term Monitoring
HbA1c remains the primary indicator of chronic glycemic control and should be measured at least every 3 months until stable, then every 3–6 months 6, 4
HbA1c reflects average glucose over the preceding 2–3 months, with 50% weighted to the most recent month 6
Each 1% reduction in HbA1c corresponds to approximately 35 mg/dL lower mean plasma glucose and significantly reduces microvascular complications 6
SMBG complements but does not replace HbA1c; daily glucose checks guide immediate therapy adjustments, while HbA1c assesses overall treatment adequacy 4, 6
Continuous Glucose Monitoring (CGM) as an Alternative
Consider CGM if SMBG reveals unexplained discrepancies between fasting values and HbA1c, or to identify nocturnal hypoglycemia patterns 2, 6
CGM provides real-time glucose trends and alerts for hypo- and hyperglycemia, which may improve outcomes in insulin-treated patients 2, 5
CGM is particularly useful when glycemic variability is high or when patients have hypoglycemia unawareness 5, 2